Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | — | $58.5K | $2.52M | $815K |
| Revenue growth | — | — | — | 4217.3% | -67.7% |
| Gross profit | — | — | -$1.13M | $1.06M | $633K |
| Gross margin | — | — | -1927.9% | 41.8% | 77.6% |
| Operating income | -$3.42M | -$13.5M | -$36.0M | -$56.5M | -$17.9M |
| Operating margin | — | — | -61634.5% | -2238.0% | -2190.0% |
| Net income | -$3.42M | -$13.4M | -$37.4M | -$58.7M | -$14.0M |
| Net margin | — | — | -63986.5% | -2325.2% | -1721.0% |
| EPS (diluted) | -$1.26 | -$1.10 | -$87.45 | -$1,823.39 | -$16.56 |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | -$2.04M | -$8.68M | -$13.6M | -$10.5M | -$9.68M |
| Capital expenditures | $1.92K | $9.34K | $3.30K | $28.5K | — |
| Free cash flow | -$2.05M | -$8.68M | -$13.6M | -$10.5M | — |
| Share buybacks | — | $567K | — | — | — |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Cash & equivalents | $1.93M | $25.8M | $4.55M | $647K | $5.22M |
| Total assets | $3.08M | $26.3M | $87.5M | $28.2M | $24.9M |
| Total liabilities | $1.64M | $3.92M | $21.9M | $18.6M | $9.16M |
| Shareholders' equity | $1.45M | $22.4M | $1.40M | $8.54M | $15.8M |
| Retained earnings | -$5.96M | -$19.4M | -$56.8M | -$116M | -$131M |
| Shares (wtd avg diluted) | 3.20M | 12.3M | 428K | 32.3B | 938K |
Every figure is extracted from Onconetix, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.